Severe obesity and cardiometabolic risk in children: comparison from two international classification systems

Giuliana Valerio1, Claudio Maffeis2, Antonio Balsamo3

  • 1Dipartimento di Scienze Motorie e del Benessere, Università degli Studi di Napoli Parthenope, Napoli, Italy.

Plos One
|January 4, 2014
PubMed

Insights

Defining severe obesity (Sev-OB) in children requires careful consideration of reference standards. The 1.2 times the 95th percentile of body mass index (BMI) better identifies children with cardiometabolic risks than the 99th percentile.

Area of Science:

  • Pediatric Endocrinology
  • Public Health Nutrition
  • Cardiology

Background:

  • A universally accepted definition for severe obesity (Sev-OB) in children is lacking.
  • Body mass index (BMI) percentile curves from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) are commonly used to define obesity in children.
  • Different cut-points within these curves may lead to varied estimates of Sev-OB and associated health risks.

Purpose of the Study:

  • To compare estimates of severe obesity (Sev-OB) in children using different body mass index (BMI) percentile cut-points from CDC and WHO growth charts.
  • To evaluate the effectiveness of these different cut-points in screening for cardiometabolic risk factors in overweight and obese children.

Main Methods:

  • A cross-sectional, multicenter study included 3,340 overweight/obese children.
  • Severe obesity (Sev-OB) was defined using two criteria: BMI ≥ 99th percentile or BMI ≥ 1.2 times the 95th percentile, based on both CDC and WHO growth curves.
  • Cardiometabolic risk factors included high blood pressure, hypertriglyceridemia, low High-Density Lipoprotein cholesterol, and impaired fasting glucose.

Main Results:

  • Prevalence estimates of Sev-OB differed significantly between CDC and WHO references, with WHO identifying a higher proportion of children as severely obese.
  • The 99th percentile cut-point showed lower sensitivity but higher specificity and positive predictive value compared to the 1.2 times the 95th percentile for identifying children with ≥ 2 cardiometabolic risk factors.
  • Using the 1.2 times the 95th percentile demonstrated substantial agreement between growth curves, particularly in children aged 10 years and younger.

Conclusions:

  • The choice of reference system (CDC vs. WHO) and BMI cut-point significantly impacts the definition of severe obesity and the identification of cardiometabolic risk in children.
  • The 1.2 times the 95th percentile of BMI, from either CDC or WHO standards, offers a better discriminatory ability for identifying severely obese children with increased cardiometabolic risk compared to the 99th percentile, especially in younger children (≤10 years).
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324